ArticleClinical and translational science2025
Pharmacogenomic and Clinical Predictors of Deferasirox Response in Transfusion-Dependent Thalassemia Identified Using Whole-Genome Sequencing.
Article in Clinical and translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacogenomic and Clinical Predictors of Deferasirox Response in Transfusion-Dependent Thalassemia Identified Using Whole-Genome Sequencing.Clinical and translational science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Deferasirox is a widely used oral iron chelator in patients with transfusion-dependent thalassemia, but considerable variability in treatment response remains a clinical challenge. This study applied whole-genome sequencing to investigate genetic predictors of deferasirox response in 88 Thai patients. This approach enabled comprehensive detection of both known and novel variants across eight key genes involved in deferasirox metabolism and transport. Two novel intronic variants in ABCC2 emerged as strong and clinically relevant predictors of treatment response. The homozygous TG deletion variant rs3047477 in ABCC2 (MAF 31.8%) was significantly associated with greater reductions in liver iron concentrations and increased iron excretion, whereas the rare variant rs188034361 was linked to poorer outcomes. Haplotype analysis identified a 69-kilobase linkage block comprising 12 tightly linked variants, grouped into distinct clusters. Clusters 3.4 and 4.4 were associated with greater reductions in serum ferritin, whereas clusters 2.2, 2.3, and 4.5 predicted suboptimal response. Two variants in UGT1A3 were found to have novel associations with deferasirox response. Specifically, the rs33979061 variant (MAF 6.8%) was associated with poorer treatment outcomes, whereas the rs540607993 variant (MAF 1.1%) predicted enhanced ferritin reduction. Previously reported associations involving UGT1A1 (*28, *6) and UGT1A3 (rs3806596) were also confirmed. Clinical factors, including baseline iron overload, transfusion intensity, body mass index, and age, also contributed to treatment variability. These findings support the implementation of pharmacogenetic profiling to guide personalized chelation strategies in patients with transfusion-dependent thalassemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.